Esther Duran

Caceres, EX 10003, Spain

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 11 publications

Expression of the inhibitory checkpoints LAG-3, TIM-3, and PD-1 in NK cells and T cells in acute myeloid leukemia: preserved expression of LAG-3 is associated with patient survival.

Expression of the inhibitory checkpoints LAG-3, TIM-3, and PD-1 in NK cells and T cells in acute myeloid leukemia: preserved expression of LAG-3 is associated with patient survival.

Journal: Cancer immunology, immunotherapy : CII

Published: May 11, 2025

Phenotypic, proteomic, and functional analyses of cytokine-induced memory-like NK cells show two distinct subsets based on CD16 expression.

Phenotypic, proteomic, and functional analyses of cytokine-induced memory-like NK cells show two distinct subsets based on CD16 expression.

Journal: Scientific reports

Published: February 20, 2025

Enhanced expression of natural cytotoxicity receptors on cytokine-induced memory-like natural killer cells correlates with effector function.

Enhanced expression of natural cytotoxicity receptors on cytokine-induced memory-like natural killer cells correlates with effector function.

Journal: Frontiers in immunology

Published: July 10, 2023

Characterization of the DNAM-1, TIGIT and TACTILE Axis on Circulating NK, NKT-Like and T Cell Subsets in Patients with Acute Myeloid Leukemia.

Characterization of the DNAM-1, TIGIT and TACTILE Axis on Circulating NK, NKT-Like and T Cell Subsets in Patients with Acute Myeloid Leukemia.

Journal: Cancers

Published: June 11, 2020

Current progress in NK cell biology and NK cell-based cancer immunotherapy.

Current progress in NK cell biology and NK cell-based cancer immunotherapy.

Journal: Cancer immunology, immunotherapy : CII

Published: September 15, 2019

DNAM-1 and the TIGIT/PVRIG/TACTILE Axis: Novel Immune Checkpoints for Natural Killer Cell-Based Cancer Immunotherapy.

DNAM-1 and the TIGIT/PVRIG/TACTILE Axis: Novel Immune Checkpoints for Natural Killer Cell-Based Cancer Immunotherapy.

Journal: Cancers

Published: May 19, 2019

Modulation of NK cells with checkpoint inhibitors in the context of cancer immunotherapy.

Modulation of NK cells with checkpoint inhibitors in the context of cancer immunotherapy.

Journal: Cancer immunology, immunotherapy : CII

Published: August 16, 2018

In Vitro Culture with Interleukin-15 Leads to Expression of Activating Receptors and Recovery of Natural Killer Cell Function in Acute Myeloid Leukemia Patients.

In Vitro Culture with Interleukin-15 Leads to Expression of Activating Receptors and Recovery of Natural Killer Cell Function in Acute Myeloid Leukemia Patients.

Journal: Frontiers in immunology

Published: February 24, 2017

Immunosenescence: limitations of natural killer cell-based cancer immunotherapy.

Immunosenescence: limitations of natural killer cell-based cancer immunotherapy.

Journal: Cancer immunology, immunotherapy : CII

Published: May 24, 2016

Natural Killer Cell Recognition of Melanoma: New Clues for a More Effective Immunotherapy.

Natural Killer Cell Recognition of Melanoma: New Clues for a More Effective Immunotherapy.

Journal: Frontiers in immunology

Published: October 23, 2015

Natural killer cell immunosenescence in acute myeloid leukaemia patients: new targets for immunotherapeutic strategies?

Natural killer cell immunosenescence in acute myeloid leukaemia patients: new targets for immunotherapeutic strategies?

Journal: Cancer immunology, immunotherapy : CII

Published: March 18, 2015

Showing 1-11 of 11

Last Updated: 09/26/2026